Why Gilead (GILD) Is Advancing Today

Drug maker Gilead (GILD) is rallying 7.5% after the company reported stronger-than-expected fourth-quarter results and provided 2025 earnings per share guidance that came in above analysts’ average estimate.

A Look at GILD’s Q4 Results and Its 2025 Guidance

The drugmaker reported Q4 earnings per share, excluding certain items, of $1.90, high above analysts’ average estimate of $1.71. In Q4 of 2023, GILD generated adjusted EPS of $1.72. The company’s revenue climbed 6.3% last quarter versus the same period a year earlier to $7.6 billion. The latter figure was $420 million over analysts’ mean outlook.

A scientist in the lab, researching the development of biopharmaceutical monoclonal antibody drugs.

For all of 2025, GILD expects EPS, excluding some items, of $7.70 to $8.10, way above analysts’ average estimate of $7.54.

Sales of the company’s widely used Biktarvy drug, a treatment for HIV, climbed 21% year-over-year in Q4 to $3.8 billion, compared with analysts’ average estimate of roughly $3.4 billion. The revenue generated by another one of the firm’s HIV treatments, Descovy, jumped 21% YOY to $616 million. The increases in the HIV drugs’ revenue “were primarily driven by higher demand, favorable inventory dynamics and higher average realized price,” GILD noted.

Meanwhile, the sales of the company’s breast cancer treatment, Trodelvy, soared 19% year-over-year to $355 million. The increase was “driven by increased demand in all regions, as well as higher average realized price,” GILD reported.

While we acknowledge the potential of GILD, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GILD but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ ALSO 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock

Disclosure: None. This article is originally published at Insider Monkey.